oral non-peptide GLP-1 agonistGLP-1 Agonists
Orforglipron
First-in-class oral small-molecule non-peptide GLP-1 receptor agonist from Eli Lilly (Foundayo). Does not require SNAC absorption enhancer. Potentially transformative for oral obesity treatment accessibility.
weight-lossoral-bioavailabilityblood-sugar-controlnon-peptideexperimental
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
First-in-class oral small-molecule non-peptide GLP-1 receptor agonist from Eli Lilly (Foundayo). Does not require SNAC absorption enhancer. Potentially transformative for oral obesity treatment access…